Senate Bill 2226 Summary

• Adds cathinone derivatives to Schedule I controlled substances, including cathinone, methcathinone, mephedrone, and MDPV, along with any compound structurally derived from 2-Amino-1-phenyl-1-propanone with specified modifications (except bupropion).

• Expands the definition of synthetic cannabinoids in Schedule I to include naphthoylindoles, naphthoylpyrroles, naphthylmethylindenes, phenylacetylindoles, cyclohexylphenols, and tetrahydro derivatives of cannabinol with similar chemical structure and pharmacological activity.

• Clarifies that synthetic cannabinoids are treated the same as marijuana under sentencing provisions, with penalties ranging from fines for 30 grams or less to life imprisonment for trafficking 10 pounds or more during a 12-month period.

• Applies the same criminal penalties for possession, distribution, and trafficking of synthetic cannabinoids as those established for marijuana and other Schedule I controlled substances.

• The act is named the DeWayne Crenshaw Act and becomes effective upon passage.